KIT and melanoma: Another phase II trial involving patients with melanoma [12/19 (74%) patients with mucosal melanoma] harboring KIT mutations or amplifications showed that nilotinib may benefit patients with KIT alterations and whose tumors progressed after treatment with imatinib; however, patients with brain metastasis did not benefit from the treatment (122).